2025
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Taylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024, 135: 260-268. PMID: 39183466, PMCID: PMC11745998, DOI: 10.1111/bju.16509.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing therapyUpfront RCRadical cystectomyCohort of patientsBladder cancerBCG-unresponsive NMIBCRetrospective cohort of patientsProgression to MIBCUpfront radical cystectomyCancer-specific survivalInstitutional review board approvalMetastasis-free survivalFood and Drug Administration criteriaRate of recurrenceReview board approvalLong-term outcomesStatistically significant differenceNodal diseaseRe-resectionSystemic immunotherapyIntravesical chemotherapyOncological outcomesOverall survivalOncological riskCold snare polypectomy: A closer look at the efficacy and limitations for polyps 10-20 mm in size
Chaptini L, Jalloul S, Karam K. Cold snare polypectomy: A closer look at the efficacy and limitations for polyps 10-20 mm in size. World Journal Of Gastrointestinal Endoscopy 2024, 16: 445-450. PMID: 39155992, PMCID: PMC11325874, DOI: 10.4253/wjge.v16.i8.445.Peer-Reviewed Original ResearchThe Safety and Efficacy of Hydroxyapatite Repair of Cholesteatoma Skull Base Defects
Shah R, Reeder A, Wilkins S, Kveton J, Schwartz N. The Safety and Efficacy of Hydroxyapatite Repair of Cholesteatoma Skull Base Defects. OTO Open 2024, 8: e151. PMID: 38863486, PMCID: PMC11165677, DOI: 10.1002/oto2.151.Peer-Reviewed Original ResearchSkull base defectsLabyrinthine fistulaTegmen defectsCanal wallBase defectsRate of postoperative infectionMedical records of patientsRate of cholesteatoma recurrenceCholesteatoma recidivism ratesSemicircular canal fistulaSensorineural hearing lossElectronic medical records of patientsRate of recurrenceRecords of patientsRepair skull base defectsInner ear fistulaNonstatistically significant differenceHydroxyapatite groupCWD surgeryCWU surgeryPostoperative audiogramsCholesteatoma recurrenceMastoid infectionHearing lossPostoperative infectionVariations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.
Tabor J, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal M, Yalcin K, Morales-Valero S, Marianayagam N, Alanya H, Elsamadicy A, Millares Chavez M, Aguilera S, Mishra-Gorur K, McGuone D, Fulbright R, Jin L, Erson-Omay E, Günel M, Moliterno J. Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group. Journal Of Neurosurgery 2024, 141: 664-672. PMID: 38518289, DOI: 10.3171/2024.1.jns231633.Peer-Reviewed Original ResearchBlack patientsSporadic meningiomasClinical outcomesGenomic profilingClinical behavior of meningiomasShorter progression-free survivalAnterior skull base tumorsClinical data of patientsHispanic patientsProgression-free survivalChromosome 1p deletionBehavior of meningiomasIncreased recurrence rateRate of recurrenceSkull base tumorsData of patientsSomatic driver mutationsNon-Black patientsShorter PFSOverall survivalAggressive meningiomasTRAF7 mutationsIntracranial meningiomasMeningioma resectionNon-black group
2022
Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases
Szabo Yamashita T, Gudmundsdottir H, Foster T, Lyden M, Dy B, Tebben P, McKenzie T. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. The American Journal Of Surgery 2022, 225: 699-702. PMID: 36270819, DOI: 10.1016/j.amjsurg.2022.10.018.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismFamilial casesSingle-center retrospective reviewSporadic casesTime to recurrenceSingle gland diseaseRate of recurrenceLong-term outcomesApparent sporadic casesSporadic groupRetrospective reviewSurgical outcomesMEN-1Pediatric patientsGland diseaseFamilial syndromesSurgical pathologyFollow-upGenetic testingPatientsRecurrenceFamily cohortSyndromeMonthsOutcomesChapter 3 Pathophysiology of radiation-induced urethral strictures and therapeutic strategies optimizing outcomes of surgical repair
Sterling J, Policastro C, Nikolavsky D. Chapter 3 Pathophysiology of radiation-induced urethral strictures and therapeutic strategies optimizing outcomes of surgical repair. 2022, 51-80. DOI: 10.1016/b978-0-323-91199-3.00008-6.Peer-Reviewed Original ResearchRadiation-induced urethral stricturesUrethral strictureReconstructive urologistsLong-term sequelaeRate of recurrenceGynecologic malignanciesMale patientsOncologic treatmentPelvic cancerRectal cancerSurgical repairUrologic issuesBladder cancerStricture diseaseRadiation therapyTherapeutic strategiesChapter 3 PathophysiologyStrictureUrologistsCancerRadiation-induced changesTreatmentTissueComplicationsSequelae
2021
Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review
Beroukhim G, Ozgediz D, Cohen PJ, Hui P, Morotti R, Schwartz PE, Yang-Hartwich, Vash-Margita A. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review. Journal Of Pediatric And Adolescent Gynecology 2021, 35: 359-367. PMID: 34843973, DOI: 10.1016/j.jpag.2021.11.003.Peer-Reviewed Original ResearchConceptsMucinous borderline ovarian tumorsBorderline ovarian tumorsOvarian tumorsYale-New Haven HospitalRetrospective chart reviewBenign ovarian tumorsBenign ovarian lesionsRate of recurrenceNew Haven HospitalAbdominal painPreoperative characteristicsChart reviewDisease recurrenceRecurrent cystsCase seriesChief complaintClinical presentationClinicopathologic featuresFemale patientsMucinous cystadenomaOvarian cystsOvarian lesionsTumor stageAdolescent patientsSubsequent surveillanceClinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites
Mutlu L, Li J, Tymon-Rosario J, Hui P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology 2021, 162: s113-s114. DOI: 10.1016/s0090-8258(21)00857-x.Peer-Reviewed Original ResearchEarly-stage diseaseHigh-grade histologyOvarian preservationAdjuvant therapyNode dissectionGrade histologyOncologic outcomesClinicopathologic characteristicsMyometrial invasionSarcomatous overgrowthPatients underwent lymph node dissectionUnderwent lymph node dissectionEvidence of diseaseLymph node dissectionNon-inferior outcomesRate of recurrencePractical management optionsCervical adenosarcomaHormonal therapyLast followPositive nodesStage diseasePremenopausal womenMedian ageBetter prognosis
2020
Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma
Catenacci D, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala M, Narula S, Alpert L, Setia N, Xiao S, Hart J, Siddiqui U, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron S, Liao C, Polite B, Kindler H, Turaga K, Prachand V, Roggin K, Ferguson M, Posner M. Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open 2020, 3: e1921290. PMID: 32058557, DOI: 10.1001/jamanetworkopen.2019.21290.Peer-Reviewed Original ResearchConceptsLocally advanced gastroesophageal adenocarcinomaPathological response gradeAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaResection rateMargin-negativeResponse gradeMargin-negative resection rateMedian disease-free survivalUGT1A1 genotype groupsMedian overall survivalLocally advanced adenocarcinomaHigher adverse eventsR0 resection rateDisease-free survivalCoprimary end pointsPhase 2 trialRate of recurrenceIntestinal-type tumorsR0 resectionR1 resectionAdvanced adenocarcinomaNeoadjuvant chemotherapyPerioperative therapyOverall survival
2019
Excisional Curettage of Benign Cystic Lesions.
Ibe IK, Alder KD, Henderson SE, Yu KE, Lee FY. Excisional Curettage of Benign Cystic Lesions. JBJS Essential Surgical Techniques 2019, 9: e24. PMID: 32021719, PMCID: PMC6948994, DOI: 10.2106/jbjs.st.18.00036.Peer-Reviewed Original ResearchBenign cystic lesionsAneurysmal bone cystCystic lesionsBone cystExcisional curettageWide resectionFeeding vesselsTreatment modalitiesInitial incisionUnicameral bone cystsLow recurrence rateRate of recurrenceGiant cell tumorCareful preoperative planningHigh-speed burrAdjuvant therapyThorough curettageSurgical treatmentTotal resectionRecurrence rateCortical windowCell tumorsCystic contentsNonossifying fibromaCurettageComparative effectiveness analysis of Pipeline device versus coiling in unruptured aneurysms smaller than 10 mm.
Malhotra A, Wu X, Miller T, Matouk CC, Sanelli P, Gandhi D. Comparative effectiveness analysis of Pipeline device versus coiling in unruptured aneurysms smaller than 10 mm. Journal Of Neurosurgery 2019, 132: 42-50. PMID: 30641830, DOI: 10.3171/2018.8.jns181080.Peer-Reviewed Original ResearchConceptsPipeline Embolization DeviceStent-assisted coilingRetreatment rateSmall unruptured aneurysmsComparative effectiveness analysisProbabilistic sensitivity analysesUnruptured aneurysmsEndovascular coilingHealth benefitsUse of PEDHigher health benefitsRate of recurrenceFavorable treatment strategyDecision-analytical studyStent-assisted techniquePED placementTreatment modalitiesEffectiveness analysisTreatment strategiesSmall aneurysmsEmbolization DeviceSimple coilingOutcome riskAneurysmsRetreatment
2017
Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: 0. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBody Mass IndexBrachytherapyConstriction, PathologicDatabases, FactualEndometrial NeoplasmsFemaleGastrointestinal DiseasesGravidityHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm StagingOvariectomyRadiation InjuriesRadiotherapy, AdjuvantSalpingectomyTreatment OutcomeVaginaVaginal DiseasesConceptsVaginal brachytherapyVaginal symptomsLate grade 3 toxicityEarly-stage endometrial cancerNormal body mass indexAdjuvant vaginal brachytherapyGrade 3 toxicityShorter vaginal lengthStage endometrial cancerEndometrial cancer patientsBody mass indexRate of recurrenceAcute gastrointestinalTreatment tolerabilityVaginal stenosisEndometrial cancerVaginal lengthMass indexRecurrence rateCancer patientsVaginal toxicityTreatment characteristicsHigh riskSide effectsPatientsDistinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations
Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il’yasova D, Krishnamurti U, Li X, Reid M, Gupta M, Rida P, Osan R, Aneja R. Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLOS ONE 2017, 12: e0170095. PMID: 28085947, PMCID: PMC5234824, DOI: 10.1371/journal.pone.0170095.Peer-Reviewed Original ResearchConceptsAdjuvant therapyNeoadjuvant chemotherapyRecurrence rateTumor recurrenceClinical studiesBreast cancer recurrence ratesBreast tumor recurrenceCohort of patientsBreast cancer patientsRate of recurrenceCancer recurrence rateAfrican American patientsFirst clinical studyHigh incidence rateEuropean American patientsForm of treatmentLocal recurrenceClinical outcomesPost therapyCancer patientsInvasive diseaseIncidence rateHigher overall rateRecurrence patternsHigh risk
2015
Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.
Miura J, Johnston F, Tsai S, George B, Thomas J, Christians K, Turaga K, Pawlik T, Gamblin T. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy. Journal Of Clinical Oncology 2015, 33: 353-353. DOI: 10.1200/jco.2015.33.3_suppl.353.Peer-Reviewed Original ResearchLymph node statusSurgically resected intrahepatic cholangiocarcinomaResected intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaNode statusMedian OSOverall survivalFrequency of lymph node metastasisNon-metastatic intrahepatic cholangiocarcinomaAssociated with shorter OSTime of surgical resectionAssessment of lymph nodesNational Cancer DatabaseLymph node evaluationCurative intent surgeryLog-rank testRate of recurrenceAdvanced tumor stageLymph node metastasisSubgroup of patientsIntrahepatic cholangiocarcinoma patientsReceipt of CTCox proportional hazards modelsProportional hazards modelBenefits of CT
2014
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal Of Clinical Oncology 2014, 32: 2142-2150. PMID: 24888816, PMCID: PMC4076026, DOI: 10.1200/jco.2013.53.1608.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm StagingPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTrastuzumabTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesConceptsDistant relapse-free survivalBN0M0 breast cancerHER2-negative tumorsBreast cancerT1a tumorsCohort studyT1b tumorsSurvival outcomesHR-positive/HER2-negative tumorsTumor subtypesNational Comprehensive Cancer Network databaseHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusHER2-negative breast cancerNode-negative breast cancerHormone receptorsConsideration of chemotherapyHER2-negative diseasePercent of patientsReceipt of chemotherapyNonrandomized cohort studyProspective cohort studyRelapse-free survivalRate of recurrenceMulti-institutional study
2012
Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG, Gamblin TC, Pawlik TM. Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients. Annals Of Surgical Oncology 2012, 19: 4036-4042. PMID: 22972507, PMCID: PMC3568525, DOI: 10.1245/s10434-012-2634-6.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalDesmoid tumorsTumor locationWorse recurrence-free survivalRare soft tissue neoplasmMajor surgical centersR0 surgical marginsDisease-free survivalEffective adjuvant therapyManagement of patientsPredictors of recurrenceRate of recurrenceMulti-institutional analysisSoft tissue neoplasmBackgroundDesmoid tumorsResultsMedian ageAdjuvant therapyMost patientsSurgical resectionMargin statusSurgical marginsSurgical centersTreatment characteristicsRecurrence patternsAbdominal cavity
2010
Non‐clamped partial nephrectomy: techniques and surgical outcomes
Smith GL, Kenney PA, Lee Y, Libertino JA. Non‐clamped partial nephrectomy: techniques and surgical outcomes. BJU International 2010, 107: 1054-1058. PMID: 21040369, DOI: 10.1111/j.1464-410x.2010.09798.x.Peer-Reviewed Original ResearchConceptsPartial nephrectomyVascular clampingGroup AGroup BSolitary kidneyRenal functionBlood lossOncological efficacyPercentage changeVon Hippel-Lindau diseaseFour-variable ModificationRenal vascular clampingMedian tumor sizeRate of complicationsRenal Disease equationGlomerular filtration rateSubset of patientsMedian percentage changeRate of recurrencePositive margin rateHippel-Lindau diseaseUnclamped groupPerioperative deathsPreoperative eGFRRetrospective reviewRecombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management
Chen MK, Doddamane I, Cheng DW. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Current Opinion In Oncology 2010, 22: 6-10. PMID: 19844179, DOI: 10.1097/cco.0b013e3283339d5d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneMetastatic thyroid cancerThyroid-stimulating hormoneThyroid cancerThyroglobulin levelsWhole body radiation exposureThyroid hormone withdrawalThyroid remnant ablationFurther prospective studiesLong-term outcomesRate of recurrenceSurveillance of patientsThyroid cancer managementBody radiation exposureNegative predictive valueRadioiodine ablationPersistent diseaseRadioiodine treatmentRemnant ablationThyroid remnantsWithdrawal patientsPatients' qualityPatient groupProspective study
2006
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 2006, 295: 1658-1667. PMID: 16609087, PMCID: PMC1459540, DOI: 10.1001/jama.295.14.1658.Peer-Reviewed Original ResearchConceptsER-positive tumorsER-positive patientsEstrogen receptor statusAdjuvant chemotherapyOverall survivalBreast cancerBreast cancer estrogen receptor statusNode-positive breast cancer patientsNode-positive breast cancerER-negative breast cancerDoxorubicin/cyclophosphamideRegimens of cyclophosphamideER-negative patientsLeukemia Group BLow-dose cyclophosphamideNode-positive tumorsBreast cancer patientsRate of recurrenceRelative risk reductionER-negative tumorsMortality rate reductionAdjuvant treatmentEndocrine therapyER statusRandomized trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply